The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from Business Wire

AstraZeneca Applauds the Release of New U.S. Guideline for Management of Blood Cholesterol

<p class='bwalignc'> <i>Guideline supports use of CRESTOR</i><sup><i>®</i></sup><i> (rosuvastatin calcium) to lower cholesterol in patients at increased risk</i> </p>

Tuesday, November 12, 2013

AstraZeneca Applauds the Release of New U.S. Guideline for Management of Blood Cholesterol

17:19 EST Tuesday, November 12, 2013

WILMINGTON, Del. (Business Wire) -- AstraZeneca (NYSE:AZN) today announced their support of the release of the “2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults,”which recommends use of statin therapy for patients across four major groups at risk for a heart attack, stroke or major cardiovascular event. This guideline was issued jointly by the American College of Cardiology (ACC) and American Heart Association (AHA).

The guideline recommends moderate- or high-intensity statin therapy for:

  • Patients who have cardiovascular disease (CVD);
  • Patients with an LDL-C, or “bad” cholesterol level of 190 mg/dL or higher;
  • Patients with Type 2 diabetes who are between 40 and 75 years of age;
  • Patients without CVD or diabetes who are between 40 and 75 years of age with an LDL-C of 70-189 mg/dL and an estimated 10-year risk of cardiovascular disease of 7.5 percent or higher

“AstraZeneca has long advocated for and educated about the importance of cardiovascular risk assessment, lifestyle change, and aggressive cholesterol lowering in patients at increased risk, and we are pleased that the new guideline provides physicians with clear definitions of these statin-eligible patients,” said Dr. Philip de Vane, Executive Director, U.S. Medical Affairs, AstraZeneca. “This reinforces the importance of CRESTOR as an appropriate treatment option in increased-risk patients.”

In a 6-week multicenter, double-blind, placebo-controlled, dose-ranging study in patients with hyperlipidemia, CRESTOR 5-40 mg has been shown to provide a 45%-63% reduction in LDL-C versus 7% with placebo. Furthermore, in high-risk patients in the ECLIPSE trial, CRESTOR reduced LDL-C significantly more than atorvastatin at each compared dose at each time point.

This guideline identifies patients most likely to benefit from statin therapy and for the first time distinguishes recommended intensity of statin therapy for specified patient groups.

“This new guideline is based on a review of multiple statin studies, including studies from the CRESTOR clinical trial program,” added Dr. de Vane. “As leaders in the field of cardiovascular disease, we are pleased that our research helped to inform the development of this important guideline.”

For a copy of the “2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults,” please visit: http://content.onlinejacc.org/article.aspx?doi=10.1016/j.jacc.2013.11.002

Approved Uses for CRESTOR ® (rosuvastatin calcium) Tablets

When diet and exercise alone aren't enough, adding CRESTOR can help. In adults, CRESTOR is prescribed along with diet to lower high cholesterol and to slow the buildup of plaque in arteries as part of a treatment plan to lower cholesterol to goal.

CRESTOR is also prescribed to reduce the risk of heart attack and stroke in people without known heart disease but at increased risk based on age (men 50 years and older, women 60 years and older), elevated blood levels of hsCRP (a sign of inflammation that can be associated with increased risk of cardiovascular events), plus at least one additional risk factor (such as high blood pressure, low HDL "good" cholesterol, smoking, or family history of early heart disease).

Important Safety Information about CRESTOR

CRESTOR is not right for everyone. Do not take CRESTOR if you are nursing, pregnant or may become pregnant; have liver problems; or have had an allergic reaction to CRESTOR. Your doctor should do blood tests to check your liver before starting treatment and if you have symptoms of liver problems while taking CRESTOR. Call your doctor right away if you have unexplained muscle pain or weakness, especially with fever; have muscle problems that do not go away even after your doctor told you to stop taking CRESTOR; feel unusually tired; or have loss of appetite, upper belly pain, dark urine, or yellowing of skin or eyes. These could be signs of rare but serious side effects. Elevated blood sugar levels have been reported with statins, including CRESTOR. The most common side effects may include headache, muscle aches, abdominal pain, weakness, and nausea. Memory loss and confusion have also been reported with statins, including CRESTOR. Tell your doctor and pharmacist about other medicines you are taking.

Talk to your doctor about prescription CRESTOR.

Please read the full Prescribing Information .

If you have any questions concerning prescription-only CRESTOR, please visit CRESTOR.com or contact AstraZeneca at 1-800-CRESTOR.

NOTES TO EDITORS

About CRESTOR

CRESTOR has received regulatory approval in more than 100 countries worldwide. CRESTOR is backed by clinical research that spans 13 years, including over 120 ongoing or completed clinical trials and includes more than 67,000 patients worldwide.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information about AstraZeneca in the U.S. or our AZ&Me™ Prescription Savings programs, please visit: www.astrazeneca-us.com or call 1-800-AZandMe (292-6363).

CRESTOR is a registered trademark, and AZ&Me is a trademark of the AstraZeneca group of companies.

©2013 AstraZeneca. All rights reserved.

2927900 11/13

AstraZeneca
Media Inquiries:
Elizabeth Renz, 302-885-1936
Elizabeth.Renz@AstraZeneca.com
or
Michele Meixell, 302-885-6351
Michele.Meixell@AstraZeneca.com

Products
  • Globe Unlimited

    Digital all access pass across devices. subscribe

  • The Globe and Mail Newspaper

    Newspaper delivered to your doorstep. subscribe

  • Globe2Go

    The digital replica of our newspaper. subscribe

  • Globe eBooks

    A collection of articles by the Globe. subscribe

See all Globe Products

Advertise with us

GlobeLink.ca

Your number one partner for reaching Canada's Influential Achievers. learn more

The Globe at your Workplace
Our Company
Customer Service
Globe Recognition
Mobile Apps
NEWS APP
INVESTING APP
Other Sections